Bill Sponsor
House Bill 6383
116th Congress(2019-2020)
Uterine Fibroid Research and Education Act of 2020
Introduced
Introduced
Introduced in House on Mar 24, 2020
Overview
Text
Introduced
Mar 24, 2020
Latest Action
Mar 24, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
6383
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Uterine Fibroid Research and Education Act of 2020

This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues).

Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies.

In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services.

Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.

Text (1)
March 24, 2020
Actions (2)
03/24/2020
Referred to the House Committee on Energy and Commerce.
03/24/2020
Introduced in House
Public Record
Record Updated
Feb 8, 2022 11:17:25 PM